Gregory Dennis
Family Medicine · Yukon, OKNPI 1508976051
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 96.8% of the total across 307 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 26 manufacturers, the largest accounting for just 11.8% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $2,324 and has fallen 99.0% since, to $23 in 2025.
Across 307 payments — averaging $12.76 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$463
- Lilly USA, LLC$430
- Amgen$427
- Pfizer$423
- Novo Nordisk$408
- Amarin Pharma, Inc.$242
- plus $2K from 20 others
What the payments were for
- Travel & lodging$50%
- Food & beverage$3,79297%
- Education$1203%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 20 | $463 |
| Lilly USA, LLC | 37 | $430 |
| Amgen(2 entities) | 31 | $427 |
| Pfizer | 43 | $423 |
| Novo Nordisk | 42 | $408 |
| Amarin Pharma, Inc. | 22 | $242 |
| Boehringer Ingelheim | 22 | $241 |
| Astellas Pharma US Inc | 11 | $227 |
| Merck | 29 | $177 |
| Si-bone, Inc. | 1 | $145 |
| Novartis | 7 | $100 |
| Sanofi-aventis U.S. LLC | 7 | $98 |
| Eisai Inc. | 5 | $95 |
| Takeda Pharmaceuticals U.S.A., Inc. | 6 | $78 |
| GSK | 4 | $69 |
| Teva Pharmaceuticals USA, Inc. | 4 | $51 |
| Johnson & Johnson | 3 | $39 |
| Corcept Therapeutics | 1 | $33 |
| AbbVie(2 entities) | 2 | $30 |
| E.r. Squibb & Sons, L.L.C. | 2 | $27 |
| Antares Pharma, Inc. | 2 | $26 |
| Genentech USA, Inc. | 2 | $26 |
| Abbott | 1 | $24 |
| IBSA Pharma Inc. | 1 | $14 |
| Dexcom, Inc. | 1 | $14 |
| Nalpropion Pharmaceuticals LLC | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- SYMBICORT$131
- FARXIGA$131
- FASENRA$131
- BREZTRI AEROSPHERE$131
How this compares
$3,918 in reported general payments places this provider in the 80th percentile of 1,730 family medicine providers in Oklahoma.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 13 | $322 |
| Gabapentin | 11 | $105 |
Paid to pharmacies, not to this prescriber.
Other family medicine in Yukon
- Marion StudebakerYukon$13K
- Alexander FrankOklahoma City$3.1M
- Stanley ShadidEdmond$363K
- Geoffrey PlumleeTulsa$297K
- Curtis HarrisAda$125K
- Melinda CailOklahoma City$122K
- Jose Maria Borrego AcostaOklahoma City$106K
- Lisa ConneryNorman$105K
- Michael RobinsonElk City$84K
- Kimberly HuttonTulsa$76K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.